AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33465285
Drug: ELX-02 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELX-02 at 5.0 mg/kg
Trial: 32889781
Drug: High hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High hormone (HH) phase
Trial: 34530059
Drug: ART (Alternative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART (Alternative Restorative Treatment)
Trial: 34248187
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (10 ml of normal saline) prior to interscalene block
Trial: 34248187
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (no saline injection)
Trial: 32289479
Drug: 8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g/day valacyclovir
Trial: 33257495
Drug: Person-Centred Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Person-Centred Therapy (PCT)
Trial: 33722999
Drug: Bromhexine 8
RxNorm normalized name: bromhexine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine 8 mg four times a day in addition to standard therapy
Trial: 33722999
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (lopinavir/ritonavir and interferon beta-1a)
Trial: 35196591
Drug: 0.1% nepafenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% nepafenac eye drops thrice daily for 2 weeks
Trial: 35196591
Drug: 0.09% bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.09% bromfenac eye drops twice daily for 2 weeks
Trial: 35288148
Drug: 1-L PEG
RxNorm normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-L PEG with low-dose ASC (50% lower ASC concentration)
Trial: 35288148
Drug: 1-L PEG
RxNorm normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-L PEG with low-dose ASC (25% lower ASC concentration)
Trial: 35288148
Drug: 1-L PEG
RxNorm normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-L PEG with low-dose ASC
Trial: 35144649
Drug: Fish Oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish Oil (FO) at a dose of 3 g/day containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Trial: 35144649
Drug: Perilla Oil
RxNorm normalized name: Perilla frutescens leaf oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perilla Oil (PO) at a dose of 3 g/day containing α-linolenic acid (ALA)
Trial: 35144649
Drug: Linseed and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linseed and Fish Oil (LFO) at a dose of 3 g/day containing EPA, DHA, and ALA
Trial: 32402523
Drug: Treatment Initiation
RxNorm normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Initiation Program (adherence intervention)
Trial: 32238091
Drug: MF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF therapy combined with chemotherapy
Trial: 32238091
Drug: Sham MF
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham MF therapy combined with chemotherapy
Trial: 33497537
Drug: Valsartan/cilnidipine (80/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/cilnidipine (80/10 mg)
Trial: 33497537
Drug: Valsartan/hydrochlorothiazide (80/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/hydrochlorothiazide (80/12.5 mg)
Trial: 32235144
Drug: Multimodal analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesic regimen including acetaminophen 1,000 mg, gabapentin 600 mg, ketamine 5 µg/kg/min, and lidocaine 1.5 mg/kg/h
Trial: 32235144
Drug: Multimodal analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesic regimen
Trial: 35104665
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg, monthly intravenous for 6 months)
Trial: 32830326
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy intervention (12-week duration)
Trial: 32830326
Drug: Therapeutic alliance
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic alliance and number of therapeutic techniques (treatment-specific predictors)
Trial: 35371277
Drug: Intensive hand
RxNorm normalized name: ALCOHOL 350 mL in 500 mL TOPICAL GEL [CLEAN UP Intensive Hand Sanitizer Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive hand training on the basis of routine rehabilitation treatment (including inducing five finger extension, forcibly pulling fingers and wrist joints, suddenly opening fist after clenching fist)
Trial: 35371277
Drug: Routine rehabilitation
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine rehabilitation treatment (including routine joint activity training, bed training, exercise therapy, and ADL ability training)
Trial: 32252674
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVA) injection followed by panretinal photocoagulation (PRP)
Trial: 34190207
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy followed by autologous stem cell transplantation (HD-ASCT)
Trial: 34209131
Drug: Pharmacogenetic dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic dosing algorithm
Trial: 34209131
Drug: Standard-of-care dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care dose adjustment
Trial: 32744512
Drug: HBsAg <20,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg <20,000 IU/ml
Trial: 33774968
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of diltiazem gel
Trial: 33774968
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no diltiazem gel)
Trial: 33657871
Drug: Auricular intradermal
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular intradermal acupuncture (AIA)
Trial: 32106792
Drug: Alendronate/Vitamin D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate/Vitamin D3 70 mg/5600 IU for 24 weeks (concomitant treatment arm, CTA)
Trial: 32106792
Drug: Alendronate/Vitamin D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate/Vitamin D3 70 mg/5600 IU starting 24 weeks after study entry (delayed treatment arm, DTA)
Trial: 32106792
Drug: No bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bone anti-resorptive therapy (standard of care, SOC)
Trial: 32535917
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon (Si) at 2 mmol L‐1
Trial: 35120306
Drug: Anti-EGFR agent
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-EGFR agent
Trial: 32183793
Drug: Dialectical Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behaviour Therapy (DBT) - weekly individual cognitive behavioural therapy sessions and a 2.5 h skills training group session twice per week for 6 months
Trial: 32183793
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual - weekly individual therapy sessions of 30-45 min with a psychotherapist or social worker
Trial: 32880104
Drug: Dialectical Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behaviour Therapy (DBT)
Trial: 35732620
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg/d for 12 weeks
Trial: 36228978
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy using methylene blue and IPL (560 to 700 nm, fluence 12 J/cm2)
Trial: 36228978
Drug: Combined fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined fractional CO2 laser and photodynamic therapy
Trial: 32331806
Drug: Two-dose MMR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose MMR vaccination at 9 months and 2.5 years
Trial: 35701778
Drug: Ninjin'yoeito (NYT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ninjin'yoeito (NYT) 7.5 g/day along with 100 mg/day iron supplementation
Trial: 35701778
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation 100 mg/day
Trial: 32467034
Drug: Nebulized N-acetyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized N-acetyl cysteine (NAC), 2 ml of 10% NAC nebulized every six hours.
Trial: 36415122
Drug: JNJ-73763989 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-73763989 (100 mg)
Trial: 36415122
Drug: JNJ-73763989 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-73763989 (200 mg)
Trial: 36415122
Drug: JNJ-73763989 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-73763989 (100 mg) and (200 mg)
Trial: 35656677
Drug: Denosumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (5 mg/0.2 mL)
Trial: 35225516
Drug: Conventional crater
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional crater chop (CC)
Trial: 34158028
Drug: mepolizumab 100
RxNorm normalized name: mepolizumab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepolizumab 100 mg SC
Trial: 35675051
Drug: 1.1% TTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1% TTP formulation containing retinol, retinyl acetate, and retinyl palmitate for 24 weeks
Trial: 35675051
Drug: 1.1% TTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1% TTP formulation
Trial: 32971155
Drug: Optimum diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimum diabetes care including Ramadan-focused education, flash glucose monitoring, dietary advice, and treatment adjustment
Trial: 35380268
Drug: Anti-inflammatory dietary
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory dietary intervention (six monthly food-preparation workshops and twelve motivational interviewing telephone calls)
Trial: 32673517
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of abdominal compression and propranolol
Trial: 35653554
Drug: Ciprofol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofol (0.4 mg/kg)
Trial: 33583009
Drug: Rare infectious
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rare infectious agents found in patients with IV drug abuse (Pseudomonas aeruginosa, Staphylococcus hominis, Citrobacter).
Trial: 34191552
Drug: Vestibular rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular rehabilitation therapy (VRT) plus modified Epley procedure for 4 weeks
Trial: 32057960
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream (1.5% twice daily)
Trial: 32057960
Drug: Vehicle (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (twice daily)
Trial: 32057960
Drug: Triamcinolone cream
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone cream (0.1% twice daily for 4 weeks then vehicle for 4 weeks)
Trial: 35041780
Drug: Balanced multielectrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced multielectrolyte solution (BMES)
Trial: 34635771
Drug: SnMP 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SnMP 3.0 mg/kg
Trial: 34635771
Drug: SnMP 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SnMP 4.5 mg/kg
Trial: 35460295
Drug: Salbutamol (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (16 mg for 4 days, then 24 mg 1½ h before exercise)
Trial: 32869587
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate dispersible tablet 5 mg, orally 3 times a day for 4 weeks.
Trial: 33931347
Drug: Multimodal physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal physical therapy intervention
Trial: 36282186
Drug: Alirocumab (15-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (15-100 mg)
Trial: 36282186
Drug: Evolocumab (21-140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (21-140 mg)
Trial: 34650017
Drug: One G
RxNorm normalized name: Arlatone G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One G rotary file
Trial: 36414206
Drug: digital cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: digital cognitive behavior therapy (dCBT)
Trial: 32202265
Drug: CGly, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGly, 800 mg kg‐1
Trial: 35183773
Drug: Atezolizumab with
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab with antibiotic use
Trial: 35183773
Drug: Atezolizumab without
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab without antibiotic use
Trial: 32321767
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with cisplatin and gemcitabine
Trial: 35297493
Drug: IL-6 inhibitors
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 inhibitors (e.g., Tocilizumab)
Trial: 34154931
Drug: Insulin syringe
RxNorm normalized name: Insulin Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin syringe reusage for more than five times
Trial: 32109313
Drug: Ketamine in
RxNorm normalized name: ketamine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine in conjunction with morphine
Trial: 32109313
Drug: Standard morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard morphine equivalent therapy alone
Trial: 33399632
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 100,000 IU of vitamin D (SG)
Trial: 33399632
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral doses of 400 IU of vitamin D (CG)
Trial: 35365179
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg alemtuzumab
Trial: 35365179
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg alemtuzumab
Trial: 33880019
Drug: Nebulized glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized glycopyrrolate (GLY) 25 ?g twice-daily (BID)
Trial: 32681596
Drug: Caffeine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (4 mg·kg‐1)
Trial: 34035087
Drug: Enhanced upper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced upper limb therapy (EULT) programme plus usual care
Trial: 35545258
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention (moderate intensity physical activity twice weekly at a centre and up to four times weekly at home, plus personalised nutritional counselling)
Trial: 36243351
Drug: S. sonnei-rEPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. sonnei-rEPA vaccine (adults)
Trial: 36243351
Drug: Control vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccines (adults)
Trial: 32649352
Drug: P2Y12 inhibition
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibition and aspirin
Trial: 34530881
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine administered every 18-24 hours, doses escalated daily (5-10 mg), for a minimum of 2 doses and a maximum of 5 doses (96 hours).
Trial: 32702001
Drug: Antibiotic prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescribed
Trial: 32702001
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic prescribed
Trial: 32342266
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of vitamin E on staple lines and anastomoses (G1)
Trial: 34475360
Drug: Amoxicillin 500
RxNorm normalized name: amoxicillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg twice daily for 7 days
Trial: 34475360
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and Placebo (both groups)
Trial: 35229407
Drug: MM-FAT (multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MM-FAT (multimodal approach to food art therapy)
Trial: 32319528
Drug: ZYN 3
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ZYN 3 mg
Trial: 32319528
Drug: ZYN 6
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ZYN 6 mg
Trial: 32319528
Drug: ZYN 8
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ZYN 8 mg
Trial: 32319528
Drug: General 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General 8 mg snus
Trial: 32319528
Drug: Longhorn Natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longhorn Natural 18 mg moist snuff
Trial: 32319528
Drug: General 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General 2 × 8 mg snus pouches
Trial: 34323443
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (0.4 microgram/kg bolus followed by 0.4 microgram/kg/h infusion)
Trial: 32709710
Drug: Regional anesthesia
RxNorm normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine)
Trial: 32709710
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia (0.5% L-bupivacaine and 1% lidocaine)
Trial: 35266409
Drug: Medication reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reduction (deprescribing antihypertensive medications)
Trial: 35266409
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (continuation of antihypertensive medications)
Trial: 33256659
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) with fluoxetine, 20 minutes of 2 mA stimulation, three times per week for 8 weeks.
Trial: 33256659
Drug: Fluoxetine only
RxNorm normalized name: Fluoxetine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine only (sham control).
Trial: 34477854
Drug: ON101 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ON101 cream (n = 122)
Trial: 35783542
Drug: Persian herbal
RxNorm normalized name: PERUVIAN BALSAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persian herbal medicine formula + routine treatment
Trial: 32643211
Drug: Traditional Oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional Oral Health Education (TOHE)
Trial: 36371742
Drug: Oxycodone-acetaminophen (opioid)
RxNorm normalized name: acetaminophen / oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone-acetaminophen (opioid)
Trial: 32663820
Drug: Chlorthalidone (CTD)
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (CTD) 12.5 mg once daily (QD)
Trial: 33665897
Drug: Willingness to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willingness to participate in randomized controlled trials of medications
Trial: 32799565
Drug: Generic empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Generic empagliflozin tablet (25 mg)
Trial: 32799565
Drug: Brand-named empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brand-named empagliflozin tablet (Jardiance®) (25 mg)
Trial: 35773718
Drug: Mobile device-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile device-based cognitive behavior therapy (CBT)